Search

Your search keyword '"Park, Wungki"' showing total 42 results
Start Over Author "Park, Wungki" Search Limiters Full Text
42 results on '"Park, Wungki"'

2. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Author

Rojas, Luis A., Sethna, Zachary, Soares, Kevin C., Olcese, Cristina, Pang, Nan, Patterson, Erin, Lihm, Jayon, Ceglia, Nicholas, Guasp, Pablo, Chu, Alexander, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Ruan, Jennifer, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Payne, George, Derhovanessian, Evelyna, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Dobrin, Anton, Sadelain, Michel, Łuksza, Marta, Cohen, Noah, Tang, Laura, Basturk, Olca, Gönen, Mithat, Katz, Seth, Do, Richard Kinh, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Mellman, Ira, Merghoub, Taha, Wolchok, Jedd D., Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., and Balachandran, Vinod P.

Published
2023
Full Text
View/download PDF

3. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Women's Health, Genetics, Cancer, Human Genome, Underpinning research, 1.1 Normal biological development and functioning, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Advisory Committees, Animals, Biomarkers, Tumor, Congresses as Topic, Disease Models, Animal, Humans, Immunotherapy, Medical Oncology, Neoplasms, Societies, Medical, Treatment Outcome, Tumor Microenvironment, Cancer immune responsiveness, Immune checkpoint inhibitor, Immune oncology, Tumor microenvironment, Tumor mutational burden, Immunogenic cell death, Biomarker, Germline molecular alterations, Somatic molecular alterations, Cancer immune phenotype, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis
Abstract

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

Published
2019

4. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Biomedical and Clinical Sciences, Immunology, Cancer, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis
Abstract

Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

Published
2019

6. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery.

Author

Dee, Edward Christopher, Ng, Victor C., O'Reilly, Eileen M., Wei, Alice C., Lobaugh, Stephanie M., Varghese, Anna M., Zinovoy, Melissa, Romesser, Paul B., Wu, Abraham J., Hajj, Carla, Cuaron, John J., Khalil, Danny N., Park, Wungki, Yu, Kenneth H., Zhang, Zhigang, Drebin, Jeffrey A., Jarnagin, William R., Crane, Christopher H., and Reyngold, Marsha

Subjects
ADENOCARCINOMA, CHEMORADIOTHERAPY, PANCREATIC surgery, RADIOTHERAPY, SURGICAL excision, OVERALL survival, RADIATION doses
Abstract

Introduction: The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We sought to evaluate the outcomes of salvage A-RT for isolated locoregional recurrence and examine the relationship between subsequent patterns of failure, radiation dose, and treatment volume. Methods: We conducted a retrospective analysis of all consecutive participants who underwent A-RT for an isolated locoregional recurrence of PDAC after prior surgery at our institution between 2016 and 2021. Treatment consisted of ablative dose (BED10 98–100 Gy) to the gross disease with an additional prophylactic low dose (BED10 < 50 Gy), with the elective volume covering a 1.5 cm isotropic expansion around the gross disease and the circumference of the involved vessels. Local and locoregional failure (LF and LRF, respectively) estimated by the cumulative incidence function with competing risks, distant metastasis-free and overall survival (DMFS and OS, respectively) estimated by the Kaplan–Meier method, and toxicities scored by CTCAE v5.0 are reported. Location of recurrence was mapped to the dose region on the initial radiation plan. Results: Among 65 participants (of whom two had two A-RT courses), the median age was 67 (range 37–87) years, 36 (55%) were male, and 53 (82%) had undergone pancreaticoduodenectomy with a median disease-free interval to locoregional recurrence of 16 (range, 6–71) months. Twenty-seven participants (42%) received chemotherapy prior to A-RT. With a median follow-up of 35 months (95%CI, 26–56 months) from diagnosis of recurrence, 24-month OS and DMFS were 57% (95%CI, 46–72%) and 22% (95%CI, 14–37%), respectively, while 24-month cumulative incidence of in-field LF and total LRF were 28% (95%CI, 17–40%) and 36% (95%CI 24–48%), respectively. First failure after A-RT was distant in 35 patients (53.8%), locoregional in 12 patients (18.5%), and synchronous distant and locoregional in 10 patients (15.4%). Most locoregional failures occurred in elective low-dose volumes. Acute and chronic grade 3–4 toxicities were noted in 1 (1.5%) and 5 patients (7.5%), respectively. Conclusions: Salvage A-RT achieves favorable OS and local control outcomes in participants with an isolated locoregional recurrence of PDAC after surgical resection. Consideration should be given to extending high-dose fields to include adjacent segments of at-risk vessels beyond direct contact with the gross disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Author

Chae, Young Kwang, Viveiros, Pedro, Lopes, Gilberto, Sukhadia, Bhoomika, Sheikh, Muhammad Mubbashir, Saravia, Diana, Florou, Vaia, Sokol, Ethan S., Frampton, Garrett M., Chalmers, Zachary R., Ali, Siraj M., Ross, Jeffrey S., Chang, Sangmin, Wang, Si, Chiec, Lauren, Rahbari, Ashkon, Mohindra, Nisha, Villaflor, Victoria, Shin, Sang Ha, Oh, Michael, Anker, Jonathan, Park, Lee Chun, Wang, Victor, Chuang, Jeffrey, and Park, Wungki

Published
2019
Full Text
View/download PDF

8. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Author

Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, and Walker, Paul R.

Published
2020
Full Text
View/download PDF

10. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Author

Florou, Vaia, primary, Floudas, Charalampos S, additional, Maoz, Asaf, additional, Naqash, Abdul Rafeh, additional, Norton, Carter, additional, Tan, Aik Choon, additional, Sokol, Ethan S, additional, Frampton, Garrett, additional, Soares, Heloisa P, additional, Puri, Sonam, additional, Swami, Umang, additional, Wilky, Breelyn, additional, Hosein, Peter, additional, Trent, Jonathan, additional, Lopes, Gilberto de Lima, additional, Park, Wungki, additional, and Garrido-Laguna, Ignacio, additional

Published
2023
Full Text
View/download PDF

12. Abstract 6421: Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)

Author

Park, Wungki, primary, O'Connor, Catherine, additional, Umeda, Shigeaki, additional, Sharma, Roshan, additional, Zhu, Yingjie, additional, Karnoub, Elias-Ramzey, additional, Varghese, Anna, additional, Soares, Kevin C., additional, Jimemez, Alejandro, additional, Yavas, Asli, additional, Yu, Kenneth H., additional, Vinod, Balachandran P., additional, Chou, Joanne F., additional, Khalil, Danny N., additional, David, Kelsen, additional, Ozkan, Hulya Sahin, additional, Basturk, Olca, additional, Capanu, Marinela, additional, Nawy, Tal, additional, Berger, Michael F., additional, Abou-Alfa, Ghassan K., additional, Reis-Filho, Jorge S., additional, Chaligne, Ronan, additional, Riaz, Nadeem, additional, Pe'er, Dana, additional, Iacobuzio-Donahue, Christine, additional, and O'Reilly, Eileen M., additional

Published
2023
Full Text
View/download PDF

13. Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Author

Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, and Walker, Paul R.

Published
2020
Full Text
View/download PDF

14. Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Author

Park, Wungki, primary, O'Connor, Catherine A., additional, Bandlamudi, Chaitanya, additional, Forman, Daniella, additional, Chou, Joanne F., additional, Umeda, Shigeaki, additional, Reyngold, Marsha, additional, Varghese, Anna M., additional, Keane, Fergus, additional, Balogun, Fiyinfolu, additional, Yu, Kenneth H., additional, Kelsen, David P., additional, Crane, Christopher, additional, Capanu, Marinela, additional, Iacobuzio-Donahue, Christine, additional, and O'Reilly, Eileen M., additional

Published
2022
Full Text
View/download PDF

16. Abstract 279: Optimal tumor metastatic gene programs in pancreatic cancer

Author

Jiménez-Sánchez, Alejandro, primary, Xie, Yubin, additional, Sharma, Roshan, additional, Chu, Tin Yi, additional, Liu, Vincent, additional, Park, Wungki, additional, Hayashi, Akimasa, additional, Umeda, Shigeaki, additional, Mazutis, Linas, additional, Nawy, Tal, additional, Iacobuzio-Donahue, Christine, additional, and Pe’er, Dana, additional

Published
2022
Full Text
View/download PDF

17. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Author

Dunbar, Andrew, primary, Bolton, Kelly L., additional, Devlin, Sean M., additional, Sanchez-Vega, Francisco, additional, Gao, Jianjiong, additional, Mones, Jodi V., additional, Wills, Jonathan, additional, Kelly, Daniel, additional, Farina, Mirko, additional, Cordner, Keith B., additional, Park, Young, additional, Kishore, Sirish, additional, Juluru, Krishna, additional, Iyengar, Neil M., additional, Levine, Ross L., additional, Zehir, Ahmet, additional, Park, Wungki, additional, Khorana, Alok A., additional, Soff, Gerald A., additional, and Mantha, Simon, additional

Published
2021
Full Text
View/download PDF

18. Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes

Author

Varghese, Anna M, primary, Singh, Isha, additional, Singh, Rituraj, additional, Kunte, Siddharth, additional, Chou, Joanne F, additional, Capanu, Marinela, additional, Wong, Winston, additional, Lowery, Maeve A, additional, Stadler, Zsofia K, additional, Salo-Mullen, Erin, additional, Saadat, Lily V, additional, Wei, Alice C, additional, Reyngold, Marsha, additional, Basturk, Olca, additional, Benayed, Ryma, additional, Mandelker, Diana, additional, Iacobuzio-Donahue, Christine A, additional, Kelsen, David P, additional, Park, Wungki, additional, Yu, Kenneth H, additional, and O’Reilly, Eileen M, additional

Published
2021
Full Text
View/download PDF

19. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Massachusetts Institute of Technology. Department of Biology, Koch Institute for Integrative Cancer Research at MIT, Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger-Zimmermann, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M., De Carvalho, Daniel D., DeNardo, David G., Galon, Jérôme, Kaufman, Howard L., Kirchhoff, Tomas, Lotze, Michael T., Luke, Jason J., Minn, Andy J., Politi, Katerina, Shultz, Leonard D., Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B., Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M., Barsan, Valentin, Bommareddy, Praveen K., Bot, Adrian, Church, Sarah E., Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S., McGee, Heather M., Monette, Anne, Murphy, Joseph F., Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F., Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H., Disis, Mary L., Fox, Bernard A., Cesano, Alessandra, Marincola, Francesco M., Massachusetts Institute of Technology. Department of Biology, Koch Institute for Integrative Cancer Research at MIT, Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger-Zimmermann, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M., De Carvalho, Daniel D., DeNardo, David G., Galon, Jérôme, Kaufman, Howard L., Kirchhoff, Tomas, Lotze, Michael T., Luke, Jason J., Minn, Andy J., Politi, Katerina, Shultz, Leonard D., Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B., Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M., Barsan, Valentin, Bommareddy, Praveen K., Bot, Adrian, Church, Sarah E., Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S., McGee, Heather M., Monette, Anne, Murphy, Joseph F., Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F., Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H., Disis, Mary L., Fox, Bernard A., Cesano, Alessandra, and Marincola, Francesco M.

Abstract

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Dete

Published
2020

20. 389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors

Author

Messersmith, Wells, primary, Rasco, Drew, additional, Bono, Johann De, additional, Wang-Gillam, Andrea, additional, Park, Wungki, additional, Nickle, David, additional, Galkin, Anna, additional, Ferguson, Beatrice, additional, Carter, Laura, additional, Zhou, Lei, additional, Dupont, Jakob, additional, Chaney, Marya, additional, Bendell, Johanna, additional, and Bruey, Jean-Marie, additional

Published
2020
Full Text
View/download PDF

21. 75 Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

Author

Bortone, Dante, primary, Vensko, Steven, additional, Entwistle, Sarah, additional, Cogdill, Alexandria, additional, Monette, Anne, additional, Najjar, Yana, additional, Sweis, Randy, additional, Tschernia, Nicholas, additional, Wennerberg, Erik, additional, Bommareddy, Praveen, additional, Haymaker, Cara, additional, Khan, Uqba, additional, McGee, Heather, additional, Park, Wungki, additional, Sater, Houssein, additional, Spencer, Christine, additional, Ascierto, Maria, additional, Barsan, Valentin, additional, Popat, Vinita, additional, Valpione, Sara, additional, Wells, Danny, additional, Thorsson, Vésteinn, additional, Zappasodi, Roberta, additional, Rudqvist, Nils, additional, and Vincent, Benjamin, additional

Published
2020
Full Text
View/download PDF

22. Abstract CT247: A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36)

Author

Wang-Gillam, Andrea, primary, Rasco, Drew W., additional, Park, Wungki, additional, O'Reilly, Eileen, additional, Messersmith, Wells, additional, DeNardo, David G., additional, Gupta, Vineet, additional, Zhou, Lei, additional, Galkin, Anna, additional, Slee, Debbie, additional, Carter, Laura L., additional, Nickle, David, additional, Tran, Rebecca, additional, Li, Jack, additional, Ferguson, Beatrice, additional, Chaney, Marya F., additional, Salter-Cid, Luisa, additional, Dupont, Jakob, additional, and Bendell, Johanna C., additional

Published
2020
Full Text
View/download PDF

24. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Author

Park, Wungki, primary, Chen, Jiapeng, additional, Chou, Joanne F., additional, Varghese, Anna M., additional, Yu, Kenneth H., additional, Wong, Winston, additional, Capanu, Marinela, additional, Balachandran, Vinod, additional, McIntyre, Caitlin A., additional, El Dika, Imane, additional, Khalil, Danny N., additional, Harding, James J., additional, Ghalehsari, Nima, additional, McKinnell, Zoe, additional, Chalasani, Sree B., additional, Makarov, Vladimir, additional, Selenica, Pier, additional, Pei, Xin, additional, Lecomte, Nicolas, additional, Kelsen, David P., additional, Abou-Alfa, Ghassan K., additional, Robson, Mark E., additional, Zhang, Liying, additional, Berger, Michael F., additional, Schultz, Nikolaus, additional, Chan, Timothy A., additional, Powell, Simon N., additional, Reis-Filho, Jorge S., additional, Iacobuzio-Donahue, Christine A., additional, Riaz, Nadeem, additional, and O'Reilly, Eileen M., additional

Published
2020
Full Text
View/download PDF

25. P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

Author

Rudqvist, Nils-Petter, primary, Zappasodi, Roberta, additional, Wells, Daniel, additional, Thorsson, Vésteinn, additional, Cogdill, Alexandria, additional, Monette, Anne, additional, Najjar, Yana, additional, Sweis, Randy, additional, Wennerberg, Erik, additional, Bommareddy, Praveen, additional, Haymaker, Cara, additional, Khan, Uqba, additional, McGee, Heather, additional, Park, Wungki, additional, Sater, Houssein Abdul, additional, Spencer, Christine, additional, Tschernia, Nicholas, additional, Ascierto, Maria, additional, Barsan, Valentin, additional, Popat, Vinita, additional, Valpione, Sara, additional, and Vincent, Benjamin, additional

Published
2020
Full Text
View/download PDF

26. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Author

Park, Wungki, primary, Mezquita, Laura, additional, Okabe, Naoyuki, additional, Chae, Young Kwang, additional, Kwon, Deukwoo, additional, Saravia, Diana, additional, Auclin, Edouard, additional, Planchard, David, additional, Caramella, Caroline, additional, Ferrara, Roberto, additional, Agte, Sarita, additional, Oh, Michael, additional, Mudad, Raja, additional, Jahanzeb, Mohammad, additional, Suzuki, Hiroyuki, additional, Besse, Benjamin, additional, and Lopes, Gilberto, additional

Published
2019
Full Text
View/download PDF

27. Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Author

Dunbar, Andrew, primary, Bolton, Kelly, primary, Devlin, Sean M., primary, Sanchez-Vega, Francisco, primary, Gao, Jianjiong, primary, Mones, Jodi V., primary, Wills, Jonathan M., primary, Kelly, Daniel, primary, Farina, Mirko, primary, Kishore, Sirish, primary, Juluru, Krishna, primary, Iyengar, Neil, primary, Hyman, David M., primary, Zehir, Ahmet, primary, Park, Wungki, primary, Khorana, Alok A, primary, Soff, Gerald A., primary, and Mantha, Simon, primary

Published
2019
Full Text
View/download PDF

28. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Author

Chae, Young Kwang, primary, Davis, Andrew A., additional, Agte, Sarita, additional, Pan, Alan, additional, Simon, Nicholas I., additional, Iams, Wade T., additional, Cruz, Marcelo R., additional, Tamragouri, Keerthi, additional, Rhee, Kyunghoon, additional, Mohindra, Nisha, additional, Villaflor, Victoria, additional, Park, Wungki, additional, Lopes, Gilberto, additional, and Giles, Francis J., additional

Published
2019
Full Text
View/download PDF

29. KRASG12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance.

Author

Yeh, Celine, Park, Wungki, and Yaeger, Rona

Subjects
*PANCREATIC cancer, *CYTOTOXIC T cells, *CANCER cells
Abstract

In an article in this issue of Developmental Cell and in a second paper in Cancer Cell , Mahadevan et al. demonstrate that KrasG12D suppression remodels the immunosuppressive microenvironment of Kras G12D pancreatic cancers, recruits activated CD8+ cytotoxic T cells, and epigenetically upregulates Fas expression in cancer cells, leading to tumor clearance via Fas/FasL-mediated apoptosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. P3.02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

Author

Saravia, Diana, primary, Laderian, Bahar, additional, Park, Wungki, additional, Desai, Amrita, additional, Vargas, Fernando, additional, Elias, Roy, additional, Warsch, Sean, additional, Mudad, Raja, additional, Ikpeazu, Chukwuemeka, additional, Ishkanian, Adrian, additional, Balfe, Lisa, additional, and Jahanzeb, Mohammad, additional

Published
2017
Full Text
View/download PDF

34. The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review.

Author

Farhat, Fadi, Torres, Alfredo, Park, Wungki, de Lima Lopes, Gilberto, Mudad, Raja, Ikpeazu, Chukwuemeka, and Abi Aad, Simon

Subjects
GOVERNMENT agencies, MARKETING, MEDLINE, ONLINE information services, ORGANIZATIONAL effectiveness, PHARMACEUTICAL industry, SYSTEMATIC reviews, PHARMACY, HUMAN growth hormone, ECONOMICS
Abstract

Abstract: Biologic agents are currently the fastest emerging segment of drug expenditure. Unlike chemically synthesized small‐molecule drugs, biologics are more complex, medicinal products produced by a living organism. They have become part of the standard of care in the treatment of a large variety of diseases, such as growth disorders, autoimmune diseases, cancer, cardiovascular illnesses, hemophilia, and rare genetic conditions, to name a few. Biosimilars, which are copies of biologics that are highly similar, were introduced in the market with an aim to offer efficacy that is not clinically different from the originator or reference product, at lower prices. We aim to clarify the concept of biosimilar, from definitions, history, market entry, challenges faced, and future evolution. For that purpose, we performed a literature search on the sites of the medicines regulatory agencies and PubMed from 1990 to 2014 with the keywords “biosimilars,” “market,” and “regulatory.” In 2006, the first biosimilar, somatropin [rDNA origin], was marketed and led the way for biosimilar drug manufacturing. As a result, manufacturers have entered a diversified competition, facing challenges in manufacturing these complex agents, such as immunogenicity and efficiency. Biosimilars are set to evolve differently in various markets, namely the U.S., Japan, the European Union, and the “pharmerging” economies. Implications for Practice: This article highlights the importance of biosimilars, as a cost‐cutting strategy, in the delivery of state‐of‐the‐art health care in developing countries, at a fraction of what a reference biological agent would cost. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

36. Abstract 2707: Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1α signaling in colorectal cancer.

Author

Ganji, Purnachandra, primary, Long, Tua-Elisabeth, additional, Mummareddi, Phani Madhuri, additional, Park, Wungki, additional, Willingham, Field F., additional, Landry, Jerome C., additional, Sullivan, Patrick, additional, Taliaferro-Smith, LaTonia, additional, Diaz, Roberto, additional, and El-Rayes, Bassel, additional

Published
2013
Full Text
View/download PDF

42. Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes.

Author

Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, Wong W, Lowery MA, Stadler ZK, Salo-Mullen E, Saadat LV, Wei AC, Reyngold M, Basturk O, Benayed R, Mandelker D, Iacobuzio-Donahue CA, Kelsen DP, Park W, Yu KH, and O'Reilly EM

Subjects
Cohort Studies, Genomics, Humans, Incidence, Carcinoma, Pancreatic Ductal epidemiology, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal therapy, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms therapy
Abstract

Background: Recent evidence suggests a rising incidence of cancer in younger individuals. Herein, we report the epidemiologic, pathologic, and molecular characteristics of a patient cohort with early-onset pancreas cancer (EOPC)., Methods: Institutional databases were queried for demographics, treatment history, genomic results, and outcomes. Overall survival from date of diagnosis was estimated using Kaplan-Meier method., Results: Between 2008 and 2018, 450 patients with EOPC were identified at Memorial Sloan Kettering. Median overall survival was 16.3  (95% confidence interval [CI] = 14.6 to 17.7) months in the entire cohort and 11.3  (95% CI = 10.2 to 12.2) months for patients with stage IV disease at diagnosis. Of the patients, 132 (29.3% of the cohort) underwent somatic testing; 21 of 132 (15.9%) had RAS wild-type cancers with identification of several actionable alterations, including ETV6-NTRK3, TPR-NTRK1, SCLA5-NRG1, and ATP1B1-NRG1 fusions, IDH1 R132C mutation, and mismatch repair deficiency. A total of 138 patients (30.7% of the cohort) underwent germline testing; 44 of 138 (31.9%) had a pathogenic germline variant (PGV), and 27.5% harbored alterations in cancer susceptibility genes. Of patients seen between 2015 and 2018, 30 of 193 (15.5%) had a PGV. Among 138 who underwent germline testing, those with a PGV had a reduced all-cause mortality compared with patients without a PGV controlling for stage and year of diagnosis (hazard ratio = 0.42, 95% CI = 0.26 to 0.69)., Conclusions: PGVs are present in a substantial minority of patients with EOPC. Actionable somatic alterations were identified frequently in EOPC, enriched in the RAS wild-type subgroup. These observations underpin the recent guidelines for universal germline testing and somatic profiling in pancreatic ductal adenocarcinoma., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results